Regeneron Pharmaceuticals will make its newly approved gene therapy for a rare, genetic form of hearing loss available for free in the U.S. The company hasn’t yet decided how much it will charge in other countries, Regeneron CEO Leonard Schleifer told CNBC on Friday. “We haven’t set a price yet, but they should pay their…
AstraZeneca‘s stock rose over 3% after Britain’s most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials. The respiratory treatment tozorakimab, reduced flare-ups of chronic obstructive pulmonary disease (COPD) in both former smokers and in the overall population versus placebo, the company said. “This marks a notable shift…
23andMe founder Anne Wojcicki speaks during a House Committee on Oversight and Government Reform hearing in Washington, D.C., on June 10, 2025. Andrew Harnik | Getty Images Anne Wojcicki, the co-founder and former CEO of 23andMe, has regained control over the embattled genetic testing company after her new nonprofit, TTAM Research Institute, outbid Regeneron Pharmaceuticals,…
Read More “Anne Wojcicki to buy back 23andMe and its data for $305 million” »
